Guideline: SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes – This guidance recommends a risk-based approach, advising against starting SGLT-2 inhibitors or GLP-1 receptor agonists in patients with three or fewer cardiovascular risk factors and without established CVD or CKD.
12 May, 2021 | 08:42h | UTCEditorial: Newer drug treatments for type 2 diabetes
Commentary on Twitter
New guideline provides risk-stratified recommendations about when to add SGLT-2 inhibitors or GLP-1 receptor agonists to existing treatment for adults with type 2 diabetes.#BMJInfographic provides an overview of the recommendations @will_s_t https://t.co/G7267xadmH pic.twitter.com/vKGj5xlm4Y
— The BMJ (@bmj_latest) May 11, 2021